The GlaxoSmithKline Payroll Part I

The following 'specialists', doctors, call them what you will, have all had ties with GlaxoSmithKline be it through sitting on panels or receiving funding. Maybe it's time they were asked to explain what the word 'Morals' means?

Hagop S. Akiskal, M.D., Professor of Psychiatry, Director of the International Mood Center, University of California at San Diego, La Jolla. Received grant or research support from Eli Lilly. Served as a consultant to Abbott, Janssen Pharmaceutica, and Eli Lilly. Served on the speakers’ bureaus of Abbott, GlaxoSmithKline, Janssen Pharmaceutica, and Eli Lilly. (http://www.wpic.pitt.edu/STANLEY/5thbipconf/introduction.htm; accessed 5/27/05)
EMAIL
----

David B. Badesch, M.D., F.C.C.P., Professor of Medicine and Clinical Director, Pulmonary Hypertension Center, University of Colorado Health Sciences Center, Denver. Served as a consultant or on a speakers bureau for Glaxo Wellcome/GlaxoSmithKline, Actelion, InterMune, Encysive, Myogen, Astra-Merck, AstraZeneca, Exhale Therapeutics/CoTherix, Forrest Labs, INO Therapeutics, and Berlex. Received research support from Glaxo Wellcome/GlaxoSmithKline, United Therapeutics, Boehringer Ingelheim, Actelion, Encysive, ICOS/Texas Biotechnologies/Encysive, Myogen, INO Therapeutics, Scleroderma Foundation, United Therapeutics, and Pfizer. (Chest 2004;126:1)
EMAIL

----

David A. Baker, M.D., Professor, Obstetrics, Gynecology, and Reproductive Medicine, and Director, Division of Infectious Diseases, Health Sciences Center, Stony Brook University, Stony Brook, NY. Speaker and researcher for GlaxoSmithKline. (Am J Obstet Gynecol. 2005; 193:1887-8.)

----

George L. Bakris, M.D., Professor of Internal Medicine and Preventive Medicine, Department of Preventive Medicine, Rush-Presbyterian-St. Luke Medical Center, Chicago. Advisor to Abbott Laboratories, Alteon Inc., AstraZeneca Pharmaceuticals LP, AusAm Biotechnologies, Inc., Biovail Corporation, BMS-Sanofi, Boehringer Ingelheim Pharmaceuticals Inc., Eli Lilly & Company, Forest Laboratories, GlaxoSmithKline, Merck & Co., Novartis Pharmaceuticals, Inc., Takeda Pharmaceuticals North America, Inc., and Wyeth Pharmaceuticals; received research support from Abbott Laboratories, Alteon Inc., AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc., Eli Lilly & Company, Forest Laboratories, GlaxoSmithKline, Merck & Company, Inc., and Novartis Pharmaceuticals, Inc.; member of the speakers' bureaus of Abbott Laboratories, Alteon Inc., AstraZeneca Pharmaceuticals LP, AusAm Biotechnologies, Inc., Biovail Corporation, BMS-Sanofi, Boehringer Ingelheim Pharmaceuticals Inc., Eli Lilly & Company, Forest Laboratories, GlaxoSmithKline, Merck & Company, Inc., Novartis Pharmaceuticals, Inc., Takeda Pharmaceuticals North America, Inc., and Wyeth Pharmaceuticals. (http://www.medscape.com/viewprogram/3599_authors; accessed 7/28/05) Received grants, served as a consultant to, and received honoraria for serving as a speaker from AstraZeneca, Abbott, Alteon, Biovail, Boehringer-Ingelheim, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Merck, Novartis, Sankyo, Sanofi and Solvay. (JAMA. 2003;289:2560-72.)
EMAIL
----

Robyn J. Barst, M.D., Director, New York Presbyterian Pulmonary Hypertension Center, New York, NY. Served as a consultant and received research support from Actelion, Encysive, Exhale Therapeutics, INO, Myogen, United Therapeutics, Pfizer and GlaxoSmithKline. Received unrestricted education grants from GlaxoSmithKline, Encysive, and Actelion. (Chest 2004;126:1)
EMAIL

----

Robert B. Belshe, M.D., Professor, Director, Division of Infectious Disease and Immunology, Saint Louis University, St. Louis, MO. Receives research support from Merck and MedImmune; receives consulting fees and/or lecture fees from MedImmune, Merck, Novartis, GlaxoSmithKline, and Sanofi. (N Engl J Med. 2007 Feb 15;356(7):685-96.)

----

Constance A. Benson, M.D., Professor of Medicine, Division of Infectious Diseases, University of California San Diego, and Member, Board of Directors, International AIDS Society–USA. Served as a scientific advisor to Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Merck, and Tibotec. (http://www.iasusa.org/people/disclosure.html; accessed 11/7/06)
EMAIL
----

Karl R. Beutner, M.D., Ph.D., Chief Medical Officer, Solano Clinical Research, Dow Pharmaceutical Sciences. Also, Associate Clinical Professor, Department of Dermatology, University of California, San Francisco. Research on the use of Valtrex (valacyclovir) to reduce the risk of transmission of genital herpes partially funded by GlaxoSmithKline Research and Development. Received consultation and lecture fees from GlaxoSmithKline, Eli Lilly, and 3M. (N. Engl. J. Med. 2003;350:11-22)

----

Alison Blenkinsopp, Ph.D., Professor of Medicines Management, Keele University, Newcastle, England. Received research funding from Servier, Pfizer, GlaxoSmithKline, and Merck Sharp & Dohme Ltd. (http://www.mca.gov.uk/aboutagency/regframework/csm/csmdoi01.pdf; accessed 7/18/03)

----

Charles L. Bowden, M.D., Professor and Chairman, Department of Psychiatry, University of Texas Health Science Center, San Antonio. Received grant or research support from Abbott, Bristol-Myers Squibb, Glaxo Wellcome, Janssen Pharmaceutica, Lilly Research, Parke-Davis, and SmithKline Beecham. Served as a consultant for Abbott, Glaxo Wellcome, Janssen Pharmaceutica, Lilly Research, Sanofi Synthelabo, and UCB Pharma. Served on the speakers’ bureau of Abbott Laboratories, Astra Zeneca, Glaxo Wellcome, Janssen Pharmaceutica, Lilly Research, and Pfizer. (http://www.wpic.pitt.edu/STANLEY/5thbipconf/introduction.htm; accessed 5/27/05) “Olanzapine in the Treatment of Recently Unresponsive Manic Illness” funded by Eli Lilly. (http://psychiatry.uthscsa.edu/Searches/SearchProfileData.asp?ID=24; accessed 3/4/05) Consultant for Abbott Laboratories, GlaxoSmithKline, Janssen, Ortho-McNeil, Eli Lilly, Sanofi-Synthelabo and UCB Pharma. Receives grant support from Abbott Laboratories, Bristol-Myers Squibb, Elan Pharmaceuticals, SmithKline Beecham (now GlaxoSmithKline), Janssen, Parke-Davis, and Eli Lilly and is a member of the speakers bureau for AstraZeneca, GlaxoSmithKline, Janssen, Eli Lilly, Pfizer, Ortho-McNeil and Sanofi Synthelabo. (Neuropsychopharmacology 2003;28:1374-82.; Conference disclosure notes; 41st Annual Meeting of the American College of Neuropsychopharmacology, December 2002, San Juan, Puerto Rico; on file with CSPI)
EMAIL

More coming soon.

Source: Integrity in Science